September 8, 2021
Authored and Edited by Kenneth S. Guerra; Elizabeth D. Ferrill; Caitlin E. O'Connell
In Belcher Pharms., LLC v. Hospira, Inc., No. 2020-1799 (Fed. Cir. Sept. 1, 2021), the Federal Circuit affirmed the district court’s holding that U.S. Patent No. 9,283,197 is unenforceable due to inequitable conduct.
The asserted claims of the ’197 patent are generally directed to pharmaceutical epinephrine formulations having a pH between 2.8 and 3.3 and certain impurity levels. The district court found that Belcher’s CSO, who was involved in the preparation of Belcher’s NDA and the prosecution of the ’197 patent, intentionally withheld a prior art reference and two prior art products that disclosed the claimed pH range and impurity levels.
The Federal Circuit affirmed, rejecting Belcher’s argument that its CSO genuinely believed the withheld prior art was immaterial. Specifically, the Court noted that Belcher’s CSO drafted the NDA and cited withheld prior art to expedite approval of its NDA. The Court further noted that during prosecution, the CSO argued that the claimed pH range was “critical” and yielded “unexpected results,” which contradicted Belcher’s arguments to the FDA. Therefore, the Court found that there was no clear error in finding that the single most reasonable inference was that Belcher’s CSO possessed specific intent to deceive the PTO.
Read a full analysis of this case on Finnegan's IP FDA Blog.
patentability, validity, defense, inequitable conduct, Food and Drug Administration (FDA), new drug application (NDA), United States Court of Appeals for the Federal Circuit (CAFC)
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.